Business
Fangzhou Inc. Appoints Healthcare Industry Veteran Wang Haijiao as Chief Executive Officer Following a Year of Record Growth and Profitability
SHANGHAI, March 26, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, today announced the appointment of Mr. WANG Haijiao as Chief Executive Officer and Executive Director, effective March 26, 2026. Mr. Wang succeeds former CEO Mr. Xie Fangmin and steps into the leadership role following a milestone year for the Company. For the fiscal year 2025, Fangzhou reported a successful financial turnaround, a
About this update from Fangzhou Inc.
[{"type":"image","alt":"Fangzhou Inc.","displaySize":"","headline":null,"caption":"Fangzhou Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":95,"url":"https://media.zenfs.com/en/globenewswire.com/912b0b077ef808f302b710d614115ef6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EaNaiqvUQalR0umOP_KM_Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMw--/https://media.zenfs.com/en/globenewswire.com/912b0b077ef808f302b710d614115ef6","width":300,"height":95}},"lazy":false},{"type":"text","content":"SHANGHAI, March 26, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, today announced the appointment of Mr. WANG Haijiao as Chief Executive Officer and Executive Director, effective March 26, 2026.","length":295,"tagName":"p"},{"type":"text","content":"Mr. Wang succeeds former CEO Mr. Xie Fangmin and steps into the leadership role following a milestone year for the Company. For the fiscal year 2025, Fangzhou reported a successful financial turnaround, achieving a net profit of RMB12.0 million and driving a 30.2% year-over-year revenue increase to RMB3.53 billion.","length":316,"tagName":"p"},{"type":"text","content":"Mr. Wang brings nearly 20 years of extensive experience in entrepreneurship, management, and investment within the healthcare industry. He holds deep expertise in digital health, precision medicine, and in vitro diagnostics (IVD). Prior to joining Fangzhou, Mr. Wang served as the deputy general manager, investment committee member, and executive partner of GTJA Investment Group, which he joined in 2014. He previously served as an investment director at Dragon Rise Capital and currently serves as a director of Guangzhou LBP Medicine Science & Technology Co., Ltd. (Stock Code: 688393.SH).","length":597,"tagName":"p"},{"type":"text","content":""I am highly honored to join Fangzhou Inc. at such a transformative period in its history," said Mr. WANG Haijiao, Chief Executive Officer of Fangzhou. "The Company has built an unparalleled digital healthcare infrastructure and recently achieved a remarkable financial turnaround. I look forward to working with the Board and our talented team to deepen our 'AI + CDM' strategy, leveraging our proprietary XS LLM to empower our network of over 250,000 physicians...